IMCR (Immunocore Holdings plc) stock: $32.00, $1.65B market cap, $880.2M cash, $767.8M EV, $2.15B fully diluted market cap. Data from Fully Diluted's biotech stocks database.
Pipeline assets
Tebentafusp (KIMMTRAK)
Approved · Active Modality: ImmTAC bispecific TCR
Target gp100
Partnerships EORTC: leading global ATOM adjuvant uveal melanoma Phase 3 trial
Indications- Metastatic uveal melanoma (Stage not disclosed)
- Advanced cutaneous melanoma (2L+) (Phase 3)
- Adjuvant uveal (ocular) melanoma (Phase 3)
Catalysts- — End 2026 (as early as)
- — 2028
Status note Approved in 39 countries for HLA-A*02:01-positive adult patients with unresectable or metastatic uveal melanoma. Additional Phase 3 trial (TEBE-AM) in advanced cutaneous melanoma nearing enrollment target.
Brenetafusp
Phase 3 · Active Modality: ImmTAC bispecific TCR
Target PRAME
Partnerships BMS: clinical trial collaboration and supply agreement; BMS provides nivolumab for PRISM-MEL-301 (no monetary consideration)
Indications- 1L advanced cutaneous melanoma (Phase 3)
- Platinum-resistant and platinum-sensitive ovarian cancer (Phase 1)
- Metastatic NSCLC (Phase 1)
Status note Phase 3 PRISM-MEL-301 (combination with nivolumab in advanced melanoma) ongoing.
IMC-P115C
Phase 1 · Active Modality: ImmTAC bispecific TCR (half-life extended)
Target PRAME
Indications- Advanced PRAME-expressing cancers (Phase 1)
Status note Half-life extended variant of brenetafusp targeting PRAME-A02.
IMC-R117C
Phase 1 · Active Modality: ImmTAC bispecific TCR
Target PIWIL1
Indications- Advanced solid tumors including colorectal cancer (Phase 1)
Status note First dose administered December 2024; testing monotherapy and combinations.
IMC-M113V
Phase 1 · Active Modality: ImmTAV bispecific TCR
Target HIV gag antigen
Indications- HIV (functional cure) (Phase 1)
Status note Enrolling multiple ascending dose portion of STRIVE trial.
IMC-I109V
Phase 1 · Active Modality: ImmTAV bispecific TCR
Target HBV envelope antigen
Indications- Chronic hepatitis B (Phase 1)
Status note Completed single ascending dose portion of Phase 1 trial; next steps to be determined in 2026.
IMC-S118AI
Phase 1 · Active Modality: ImmTAAI bispecific (PD1 agonist)
Target Pre-pro-insulin peptide (PPI)
Indications- Type 1 diabetes (Phase 1)
Catalysts- — Coming weeks (as of Q2 2026)
Status note CTA submitted December 2025; Phase 1 sites open.
IMC-U120AI
Preclinical · Active Modality: ImmTAAI bispecific (CD1a-tethered PD1 agonist)
Target CD1a
Indications- Atopic dermatitis (Preclinical)
Status note Preclinical.
Per-asset detail extracted from the 10-Q filed 2026-08-06. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.